Industry
Biotechnology
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 7:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 6:02 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 4:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.